“Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages,” says urologist Scott P. Campbell, MD.
In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.
Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in…
“To answer this question, one must know what is and is not included in the global payment for the UDS, and the definition and instructions…
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
“At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable…
“Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate,” says…
“I cannot overstate the impact of this device on my management of kidney stone patients,” says J. Stuart Wolf, Jr., MD, FACS.
“This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who…
“For those who do enucleations, I think I would encourage people to highly consider adopting an apical release technique if they haven’t,” says Daniel J.…
